CD3+/CD4+ cells combined with myosteatosis predict the prognosis in patients who underwent gastric cancer surgery
View abstract on PubMed
Summary
This summary is machine-generated.Lymphocyte subsets and body composition predict outcomes after gastric cancer surgery. Combining CD3+/CD4+ cells with myosteatosis improves risk identification for patients.
Area Of Science
- Oncology
- Immunology
- Radiology
Background
- Gastric cancer surgery outcomes are influenced by patient factors.
- Predictive markers for post-operative prognosis are crucial.
Purpose Of The Study
- Investigate the predictive capacity of lymphocyte subpopulations, sarcopenia, and myosteatosis for clinical outcomes in gastric cancer surgery patients.
- Explore the prognostic significance of CD3+/CD4+ cells combined with myosteatosis.
Main Methods
- Retrospective analysis of 190 gastric cancer surgery patients.
- Evaluation of peripheral lymphocyte subpopulations and body composition (sarcopenia, myosteatosis) via CT scans.
- Statistical analysis including Cox regression and nomogram development for survival prediction.
Main Results
- Elevated CD3+/CD4+ cells and CD4+/CD8+ ratios, along with diminished CD19+ cells, correlated with survival.
- Sarcopenia and myosteatosis were associated with reduced overall survival (OS).
- Multivariate analysis identified tumor stage, CD19+ cells, sarcopenia, and CD3+/CD4+ cell-myosteatosis as independent prognostic factors.
Conclusions
- Lymphocyte subsets (CD3+/CD4+, CD4+/CD8+ ratio, CD19+) and body composition (sarcopenia, myosteatosis) significantly impact gastric cancer surgery prognosis.
- The combination of CD3+/CD4+ cells and myosteatosis offers enhanced prognostic value.
- This combined marker aids in identifying high-risk patients for post-operative metastasis and recurrence.

